Gian Camenisch - Concepedia

Author

Gian Camenisch

Novartis (Switzerland)ORCID

Also Known As

Camenisch, Gian, Camenisch, Gian Peter, Gian Camenisch, Gian P. CAMENISCH, Gian P. Camenisch

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical Research University of Basel ETH Zurich Roche (Switzerland)

About

Gian Camenisch is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	21	1.4K
2	Health Sciences	3	3	126
3	Natural Sciences	3	3	69
4	Engineering	2	2	251
5	Social Sciences	1	1	67

Gian Camenisch

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight Gian Camenisch, Jochem Alsenz, H. Van De Waterbeemd, European Journal of Pharmaceutical Sciences Membrane FormationDiffusion ResistancePassive DiffusionCaco-2 Cell MonolayersMedicine	1998	341
Estimation of Caco‐2 Cell Permeability using Calculated Molecular Descriptors H. Van De Waterbeemd, Gian Camenisch, Gerd Folkers, Quantitative Structure-Activity Relationships Membrane StructureEngineeringMembrane CharacterizationAbstract PermeabilityAnalytical Ultracentrifugation	1996	202
Prediction of Organic Anion-Transporting Polypeptide 1B1- and 1B3-Mediated Hepatic Uptake of Statins Based on Transporter Protein Expression and Activity Data Annett Kunze, Jörg Huwyler, Gian Camenisch, Drug Metabolism and Disposition	2014	110
Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P‐Glycoprotein in the Disposition of Aliskiren Sujata Vaidyanathan, Gian Camenisch, Helmut Schuetz, The Journal of Clinical Pharmacology Molecular PharmacologyMetabolic PathwaysPharmacokinetic ModelingBiochemistryHealthy Subjects	2008	103
Influence of breast cancer resistance protein (Abcg2) and p‐glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec<sup>®</sup>) across the mouse blood–brain barrier Sébastien Bihorel, Gian Camenisch, Michel Lemaire, Journal of Neurochemistry High-grade GliomasCancer BiologyGliomaTumor BiologyNeuro-oncology	2007	98
On the Antimicrobial and Hemolytic Activities of Amphiphilic <i>β</i> ‐Peptides Per I. Arvidsson, Jens Frackenpohl, Neil S. Ryder, ChemBioChem	2001	98
The outstanding metabolic stability of a <sup>14</sup>C‐labeled <i>β</i>‐nonapeptide in rats – <i>in vitro</i> and <i>in vivo</i> pharmacokinetic studies Hansjörg Wiegand, B. Wirz, Alain Schweitzer, Biopharmaceutics & Drug Disposition	2002	81
Predicting human hepatic clearance from<i>in vitro</i>drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug–drug interactions Gian Camenisch, Kenichi Umehara Biopharmaceutics & Drug Disposition	2012	76
Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite Ulrike Glaenzel, Yi Jin, Regine Hansen, Drug Metabolism and Disposition	2020	68
Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters Annett Kunze, Jörg Huwyler, Gian Camenisch, Biochemical Pharmacology Hepatic Drug TransportersHepatologyAntiviral Drug TelaprevirMedicineAntiviral Drug Development	2012	67

Page 1